VNDA vs. OPK, DVAX, INVA, ZBIO, GERN, MYGN, VSTM, LXRX, RIGL, and EBS
Should you be buying Vanda Pharmaceuticals stock or one of its competitors? The main competitors of Vanda Pharmaceuticals include OPKO Health (OPK), Dynavax Technologies (DVAX), Innoviva (INVA), Zenas BioPharma (ZBIO), Geron (GERN), Myriad Genetics (MYGN), Verastem (VSTM), Lexicon Pharmaceuticals (LXRX), Rigel Pharmaceuticals (RIGL), and Emergent Biosolutions (EBS). These companies are all part of the "biotechnology" industry.
Vanda Pharmaceuticals vs. Its Competitors
OPKO Health (NASDAQ:OPK) and Vanda Pharmaceuticals (NASDAQ:VNDA) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, risk, dividends and valuation.
OPKO Health has a beta of 1.5, suggesting that its stock price is 50% more volatile than the S&P 500. Comparatively, Vanda Pharmaceuticals has a beta of 0.74, suggesting that its stock price is 26% less volatile than the S&P 500.
64.6% of OPKO Health shares are held by institutional investors. Comparatively, 88.1% of Vanda Pharmaceuticals shares are held by institutional investors. 49.7% of OPKO Health shares are held by company insiders. Comparatively, 10.0% of Vanda Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
OPKO Health currently has a consensus price target of $2.63, indicating a potential upside of 72.70%. Vanda Pharmaceuticals has a consensus price target of $16.50, indicating a potential upside of 206.69%. Given Vanda Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Vanda Pharmaceuticals is more favorable than OPKO Health.
In the previous week, OPKO Health had 3 more articles in the media than Vanda Pharmaceuticals. MarketBeat recorded 5 mentions for OPKO Health and 2 mentions for Vanda Pharmaceuticals. Vanda Pharmaceuticals' average media sentiment score of 0.62 beat OPKO Health's score of 0.50 indicating that Vanda Pharmaceuticals is being referred to more favorably in the news media.
OPKO Health has a net margin of -26.68% compared to Vanda Pharmaceuticals' net margin of -32.90%. Vanda Pharmaceuticals' return on equity of -12.89% beat OPKO Health's return on equity.
Vanda Pharmaceuticals has lower revenue, but higher earnings than OPKO Health. OPKO Health is trading at a lower price-to-earnings ratio than Vanda Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
OPKO Health beats Vanda Pharmaceuticals on 9 of the 16 factors compared between the two stocks.
Get Vanda Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for VNDA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding VNDA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Vanda Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:VNDA) was last updated on 10/16/2025 by MarketBeat.com Staff
